DexCom (DXCM) stock plummets Friday morning — carrying into the market open — after missing second quarter revenue estimates and lowering its full-year revenue guidance. The company manufactures and distributes glucose monitoring systems used in treating diabetes.

Seana Smith and Jared Blikre break down DexCom's earnings figures, how GLP-1 weight-loss drug trends may be impacting it, and how analyst teams are reassessing their outlook on the stock.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Luke Carberry Mogan.